MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Merck & Co Inc.

Abierto

SectorSanidad

80.54 3.35

Resumen

Variación precio

24h

Actual

Mínimo

77.77

Máximo

79.93

Métricas clave

By Trading Economics

Ingresos

583M

3.7B

Ventas

-1B

16B

P/B

Media del Sector

11.55

57.333

BPA

1.72

Rentabilidad por dividendo

4.15

Margen de beneficios

23.963

Empleados

73,000

EBITDA

1.3B

6.9B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+35.27% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

4.15%

2.63%

Fecha Próximo Dividendo

7 jul 2025

Próxima Fecha de Ex Dividendo

16 jun 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-56B

196B

Apertura anterior

77.19

Cierre anterior

80.54

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Merck & Co Inc. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 abr 2025, 18:18 UTC

Principales Movimientos del Mercado

Pharma Shares Reverse Losses After Tariff Pause

9 abr 2025, 09:39 UTC

Principales Movimientos del Mercado

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4 feb 2025, 12:33 UTC

Ganancias

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4 feb 2025, 11:57 UTC

Ganancias

Merck 4Q Sales Increase Results in Swing to Profit

24 abr 2025, 20:08 UTC

Ganancias

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 abr 2025, 16:05 UTC

Principales Noticias
Ganancias

Merck Cuts 2025 Outlook on Tariffs, Charges -- Update

24 abr 2025, 14:36 UTC

Charlas de Mercado
Ganancias

Merck's Challenges with Gardasil in China Continue -- Market Talk

24 abr 2025, 14:10 UTC

Charlas de Mercado
Ganancias

Merck's Mostly Steady Guidance Sees Current Tariffs Being Absorbed -- Market Talk

24 abr 2025, 11:35 UTC

Ganancias

Merck Lowers Earnings Guidance and Says Tariffs Will Hit Margins -- Barrons.com

24 abr 2025, 10:58 UTC

Principales Noticias
Ganancias

Merck 1Q Net Up, But 2025 Adj EPS View Cut on Tariffs, Charges

24 abr 2025, 10:55 UTC

Ganancias

Merck Stock Rises After Earnings Even as Keytruda Sales Miss Estimates. Here's Why. -- Barrons.com

24 abr 2025, 10:31 UTC

Ganancias

Merck: 2025 Outlook Absorbs Estimated $200 Million Additional Costs for Tariffs Implemented to Date >MRK

24 abr 2025, 10:30 UTC

Ganancias

Merck 1Q Keytruda Sales $7.21B >MRK

24 abr 2025, 10:30 UTC

Ganancias

Merck 1Q Pharmaceutical Sales $13.64B >MRK

24 abr 2025, 10:30 UTC

Ganancias

Merck 1Q Keytruda Sales Up 4% >MRK

24 abr 2025, 10:30 UTC

Ganancias

Merck 1Q Januvia/Janumet Sales Up 19% >MRK

24 abr 2025, 10:30 UTC

Ganancias

Merck 1Q Pharmaceutical Sales Down 3% >MRK

24 abr 2025, 10:30 UTC

Ganancias

Merck 1Q Gardasil/Gardasil 9 Sales $1.33B >MRK

24 abr 2025, 10:30 UTC

Ganancias

Merck 1Q Januvia/Janumet Sales $796M >MRK

24 abr 2025, 09:13 UTC

Acciones populares

Stocks to Watch Thursday: IBM, Tesla, Chipotle -- WSJ

24 mar 2025, 05:00 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5 mar 2025, 19:42 UTC

Principales Noticias

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 mar 2025, 10:30 UTC

Principales Noticias

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5 feb 2025, 12:00 UTC

Principales Noticias

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4 feb 2025, 14:48 UTC

Ganancias

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4 feb 2025, 11:51 UTC

Ganancias

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4 feb 2025, 11:50 UTC

Ganancias

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4 feb 2025, 11:31 UTC

Ganancias

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4 feb 2025, 11:31 UTC

Ganancias

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4 feb 2025, 11:31 UTC

Ganancias

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

Comparación entre iguales

Cambio de precio

Merck & Co Inc. previsión

Precio Objetivo

By TipRanks

35.27% repunte

Estimación a 12 Meses

Media 108 USD  35.27%

Máximo 138 USD

Mínimo 85 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Merck & Co Inc. Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

18 ratings

11

Comprar

7

Mantener

0

Vender

Puntuación técnica

By Trading Central

77.85 / 80.02Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.